Evidence map›Paper›PMID 32814843›Full record

ArticleProstate cancer and prostatic diseases2021

Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer.

Shiva M Nair, Max Peters, Piet Kurver, Arnon Lavi, Joost J C Verhoeff, Jochem R N van der Voort van Zyp, Marieke J van Son, Joseph L Chin

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. A Canadian center's experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Review
  5. Article
  6. Local salvage ablation therapy after radiation therapy for prostate cancer - are we there yet?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Shiva M NairDepartments of Urology and Oncology, Western University, London, ON, Canada.ORCID http://orcid.org/0000-0002-1075-3730
Max PetersDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands.ORCID http://orcid.org/0000-0002-7981-5768
Piet KurverDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands.
Arnon LaviDepartments of Urology and Oncology, Western University, London, ON, Canada.
Joost J C VerhoeffDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands.ORCID http://orcid.org/0000-0001-9673-0793
Jochem R N van der Voort van ZypDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands.
Marieke J van SonDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands.ORCID http://orcid.org/0000-0002-1886-6385
Joseph L ChinDepartments of Urology and Oncology, Western University, London, ON, Canada. joseph.chin@lhsc.on.ca.
University Medical Center Utrecht · NLWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn men with recurrence of prostate cancer post radiation therapy, further treatment remains a challenge. The default salvage option of androgen-deprivation therapy (ADT) has adverse effects. Alternatively, selected men may be offered salvage therapy to the prostate. Herein, we present long-term oncological outcomes of two whole-gland ablation techniques, cryotherapy (sCT) and high-intensity-focused ultrasound (sHIFU).

methodsMen undergoing sCT (1995-2004) and sHIFU (2006-2018) at Western University were identified. Oncological endpoints included biochemical recurrence (BCR), ADT initiation, metastases, castration resistance (CRPC), and prostate cancer-specific mortality (PCSM). Survival analysis with competing risks of mortality was performed. Multivariable analysis was performed using Fine and Gray regression.

resultsA total of 187 men underwent sCT and 113 sHIFU. Mean (SD) age of the entire cohort was 69.9 (5.9 years), median pre-radiation PSA 9.6 ng/ml (IQR 6.1-15.2), and pre-salvage PSA 4.5 ng/ml (IQR 2.8-7.0). Median total follow-up was 116 months (IQR 67.5-173.8). A total of 170 (57.6%) developed BCR, 68 (23.4%) metastases, 143 (49.3%) were started on ADT, 58 (20.1%) developed CRPC, and 162 (56%) patients died of which 59 (36.4%) were of prostate cancer. On multivariable analysis, sHIFU (HR 1.65, 95% CI 1.15-2.36, p = 0.006) and pre-salvage PSA (HR 1.09, 95% CI 1.06-1.13, p < 0.0001) were associated with a higher risk of BCR. Similarly, sHIFU patients had a higher risk of CRPC (HR 2.31, 95% CI 1.23-4.35, p = 0.009). The cumulative incidence (for both treatments) of PCSM was 16.5% (95% CI 12.2-21.4%) at 10 years and 28.4% (95% CI 22.1-34.9%) at 20 years, with no difference between treatment modalities. Pre-salvage PSA was a common predictor for the measured oncological outcomes.

conclusionsAlthough sHIFU had higher BCR and CRPC rates, there were no differences in PCSM when compared with sCT. The long-term oncological data on two ablation techniques highlighted that only 50% of patients started ADT after 10-year follow-up.

Indexed as

Ablation TechniquesAgedAndrogen AntagonistsBiomarkers, TumorCryotherapyDisease ProgressionFollow-Up StudiesHigh-Intensity Focused Ultrasound AblationHumansMaleNeoplasm Recurrence, LocalProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesSalvage TherapyAndrogen AntagonistsBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID32814843
OpenAlexW3051475848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.